News >

Spectrum Withdraws Application for Eflapegrastim in Chemo-Induced Neutropenia

Gina Columbus @ginacolumbusonc
Published: Friday, Mar 15, 2019

Joe Turgeon

Joe Turgeon

Spectrum Pharmaceuticals has voluntarily withdrawn their biologics license application (BLA) for eflapegrastim (Rolontis), due to the company needing more time to complete the FDA’s request for additional manufacturing-related information.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication